Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib Roll-over Study
NCT01735955Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2013
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 4 trial of nilotinib in chronic myeloid leukemia (CML), gastrointestinal stromal tumor (GIST), acute lymphoblastic leukemia (ALL), melanoma, sponsored by Novartis. Started Mar 2013; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)gastrointestinal stromal tumor (GIST)acute lymphoblastic leukemia (ALL)melanoma
Beyond the preview
Go deeper on NCT01735955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01735955.